menu search

ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results

ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results
Key Highlights: Continued progress has been made in advancing an investigator-initiated clinical trial to gain human proof-of-concept for Cholesterol Efflux Mediator™ VAR 200 in patients with renal disease Announced publication of several peer-reviewed journal articles supporting ASC inhibition as a promising therapeutic target – data continue to demonstrate that multiple types of inflammasomes are activated […] The post ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Res... Read More
Posted: May 12 2023, 13:07
Author Name: forextv
Views: 081748

Search within

Pages Search Results: